Emilio Batagelj

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases

Leandro Marcelo Martinez, Valeria Fernández Vallone, Vivian Labovsky et al. · Clinical & Experimental Metastasis · 2013 · 51 citations · Full text

Medicine, Cancer Biology, Oncology +17

Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis

Valeria Fernández Vallone, Erica Leonor Hofer, Hosoon Choi et al. · Clinical & Experimental Metastasis · 2012 · 24 citations · Full text

Medicine, Cell Biology, Oncology +15

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina

Claudio Martín, Lorena Lupinacci, Florencia Perazzo et al. · Clinical Lung Cancer · 2020 · 23 citations

Pharmacy, Oncology, Pharmacotherapy +8